Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 29th Congress of the European Hematology Association (EHA) was held in Madrid, Spain, and online, from June 13-16, 2024. This meeting brought together world-leading clinicians and researchers to network and share cutting-edge updates in the diagnosis, treatment, and management of hematological malignancies.
View all videos

EHA 2024

The 29th Congress of the European Hematology Association
13–16 June 2024 | Madrid, Spain/Online

EHA 2024

The 29th Congress of the European Hematology Association
13–16 June 2024 | Madrid, Spain/Online
The 29th Congress of the European Hematology Association (EHA) was held in Madrid, Spain, and online, from June 13-16, 2024. This meeting brought together world-leading clinicians and researchers to network and share cutting-edge updates in the diagnosis, treatment, and management of hematological malignancies.
View all videos

Latest videos

View all videos
2:39
Racial and ethnic disparities in AML: outcomes for Hispanic patients
Sharlene Dong • 26 Jun 2024
3:56
The association between hemophilia and fracture risk: a systematic review and meta-analysis
Eleni Gavriilaki • 23 Aug 2024
2:49
Results from the Phase III ECHO trial of acalabrutinib plus BR in MCL
Michael Wang • 14 Aug 2024
0:55
The significance of CR as an endpoint in frail patients with multiple myeloma
Meral Beksac • 13 Jun 2024

Press briefings

View all
6:37
BrECADD regimen is superior in treating advanced HL: results from the HD21 trial
Peter Borchmann • 14 Jun 2024
4:34
Development and evaluation of a novel CAR-T cell therapy against CALR mutant neoplasms
Alex Rampotas • 14 Jun 2024
4:58
LMWH does not prevent VTE in adults with newly diagnosed ALL: side study of the HOVON-100 trial
Mandy Lauw • 14 Jun 2024
3:57
IMROZ: Isa-VRd vs VRd for transplant-ineligible newly diagnosed multiple myeloma
Thierry Facon • 14 Jun 2024

Multiple Myeloma

View all
0:55
The significance of CR as an endpoint in frail patients with multiple myeloma
Meral Beksac • 13 Jun 2024
3:26
New approaches to treating transplant-ineligible multiple myeloma: triplets and quadruplets
Meral Beksac • 13 Jun 2024

Acute Myeloid Leukemia

View all
2:39
Racial and ethnic disparities in AML: outcomes for Hispanic patients
Sharlene Dong • 26 Jun 2024
1:59
Phase I study of pevonedistat, azacitidine, and venetoclax in patients with R/R AML
Guru Subramanian Guru Murthy • 11 Jul 2024

Chronic Lymphocytic Leukemia

View all
1:44
The impact of acalabrutinib treatment by line of therapy in patients with CLL
Paolo Ghia • 15 Jun 2024
1:09
Assessing cardiovascular tolerability of zanubrutinib vs ibrutinib in pts with B-cell malignancies
Jennifer Brown • 14 Jun 2024

Myeloproliferative Neoplasms

View all
5:39
Introducing the MyMPNVoice app: a patient support tool and research study
Patrick Harrington • 13 Jun 2024
1:22
Exciting upcoming MPNs trials: V617F-targeted JAK2 inhibitors and anti-calreticulin antibodies
Jean-Jacques Kiladjian • 19 Jun 2024

Myelodysplastic Syndromes

View all
1:53
Advancements in prolonging remission post-transplant in myeloid malignancies
Guru Subramanian Guru Murthy • 11 Jul 2024
2:16
The potential use of proteomics for predicting relapse in patients with MDS undergoing alloSCT
Guru Subramanian Guru Murthy • 11 Jul 2024

Lymphoma

View all
2:49
Results from the Phase III ECHO trial of acalabrutinib plus BR in MCL
Michael Wang • 14 Aug 2024
1:48
The potential of bispecific antibody-containing combinations in patients with B-cell lymphomas
Umberto Vitolo • 15 Jun 2024

Non-Malignant

View all
3:56
The association between hemophilia and fracture risk: a systematic review and meta-analysis
Eleni Gavriilaki • 23 Aug 2024
0:47
Novel agents being explored for the treatment of immune-mediated TTP
Júlia Weisinger • 14 Jul 2024

Trial Updates

View all
2:49
Results from the Phase III ECHO trial of acalabrutinib plus BR in MCL
Michael Wang • 14 Aug 2024
3:26
New approaches to treating transplant-ineligible multiple myeloma: triplets and quadruplets
Meral Beksac • 13 Jun 2024

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals